Table of Contents
DNA Vaccines: Technologies and Global Markets
Chapter- 1: INTRODUCTION -- Complimentary
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- INTENDED AUDIENCE
- SCOPE OF REPORT
- METHODOLOGY
- INFORMATION SOURCES
- RELATED BCC REPORTS
- ANALYST CREDENTIALS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter-2: SUMMARY
- SUMMARY
- SUMMARY TABLE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH
2014 ($ MILLIONS)
- SUMMARY FIGURE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH
2014 ($ MILLIONS)
- SUMMARY (CONTINUED)
Chapter-3: OVERVIEW
- INTRODUCTION
- TABLE 1 CLINICAL STATUS OF DNA VACCINES, AS OF JULY 2009 (NUMBER)
- DNA VACCINE TECHNOLOGIES COVERED IN THIS REPORT
- TABLE 2 SCOPE OF THIS REPORT
- GLOBAL MARKET FOR DNA VACCINES
- TABLE 3 GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 4 GLOBAL VALUE OF HUMAN DNA VACCINE MARKET BY INDICATION, THROUGH 2014 ($ MILLIONS)
- FORCES DRIVING DNA VACCINE MARKET GROWTH
- TABLE 5 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
- LIFE CYCLE STATUS OF DNA VACCINE TECHNOLOGIES
- TABLE 6 LIFE CYCLE STAGE OF VACCINE TYPES
- COMMERCIAL STATUS OF DNA VACCINE TECHNOLOGIES
- TABLE 7 COMMERCIAL STATUS OF DNA VACCINES
- DNA VACCINE INDUSTRY
- TABLE 8 DNA VACCINE INDUSTRY STRUCTURE
Chapter-4: DNA VACCINE TECHNOLOGIES
- HISTORY
- TABLE 9 DNA VACCINE HISTORY
- THE HUMAN IMMUNE SYSTEM
- TABLE 10 COMPONENTS OF THE IMMUNE SYSTEM
- THE HUMAN IMMUNE SYSTEM (CONTINUED)
- VACCINES
- VACCINE EVOLUTION
- FIGURE 1 EVOLUTION OF VACCINE TECHNOLOGIES
- VACCINE TYPES
- Technology Life-Cycle Stage of Vaccine Types
- TABLE 12 TECHNOLOGY LIFE-CYCLE STAGE OF VACCINE TYPES
- DNA VACCINES
- INTRODUCTION
- FIGURE 2 MECHANISM OF ACTION OF A DNA VACCINE
- CHANGING VACCINE PARADIGM
- TABLE 13 CHANGING VACCINE PARADIGM
- TABLE 14 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES
- Changing Vaccine Paradigm (Continued)
- FIGURE 3 SAFETY AND EFFICACY PROFILE OF DNA VERSUS VIRAL-VECTOR VACCINES
- FUNCTION AND SCOPE OF DNA VACCINES
- FIGURE 4 DNA VACCINE FUNCTION AND MARKET SCOPE
- TABLE 15 EMERGING COMPETITIVE LANDSCAPE FOR DNA VACCINES
- CANCER DNA VACCINES
- TABLE 16 CANCER VACCINE TYPES
- DNA VACCINE TECHNOLOGY VALUE CHAIN
- FIGURE 5 DNA VACCINE TECHNOLOGY VALUE CHAIN
- TABLE 17 TECHNOLOGY DRIVERS FOR DNA VACCINE VALUE CHAIN
- ANTIGEN DISCOVERY
- PLASMID DESIGN
- TABLE 18 PLASMID DESIGN OBJECTIVES
- TABLE 19 WAYS TO OPTIMIZE MAMMALIAN GENE EXPRESSION IN PLASMID DNA
- Plasmid Design (Continued)
- PLASMID MANUFACTURE
- FIGURE 6 CONVENTIONAL AND PLASMID DNA VACCINE PRODUCTION PROCESS
- TABLE 20 DNA PLASMID QUALITY COMPARSION
- DELIVERY TECHNOLOGIES
- TABLE 21 COMPARISON OF DNA DELIVERY TECHNOLOGIES
- Uncomplexed pDNA
- Electroporation
- FIGURE 7 EP PROCESS SCHEMATIC
- Liposomes
- Gold Particles
- Nanoparticles
- Bacterial Ghosts
- Bacteriophages
- Viruses
- TABLE 22 IN VIVO VIRAL VECTOR TECHNOLOGIES COMPARED
- Viruses (Continued)
- TARGETING TECHNOLOGIES
- FIGURE 8 STRATEGIES FOR TARGETING DENDRITIC CELLS
- ADJUVANT TECHNOLOGIES
- TABLE 23 DNA VACCINE ADJUVANT TECHNOLOGIES
- DNA VACCINE TECHNOLOGY NEEDS
- TABLE 24 TECHNOLOGY NEEDS FOR DNA VACCINES
- DNA Vaccine Technology ...... (Continued)
Chapter-5: DNA VACCINE APPLICATIONS
- RESEARCH TOOLS APPLICATIONS
- CLINICAL APPLICATIONS
- OVERVIEW TO DNA VACCINE CLINICAL TRIALS PROCESS
- TABLE 25 DNA VACCINE DEVELOPMENT FLOWSHEET
- TABLE 26 DNA VACCINE PRECLINICAL DEVELOPMENT STEPS
- FIGURE 9 FUTURE VACCINE CLINICAL TRIALS OVERVIEW
- Overview to DNA ...... (Continued)
- DNA VACCINE CLINICAL TRIALS SUMMARY
- TABLE 27 DNA VACCINES CLINICAL TRIALS SUMMARY BY DISEASE TYPE, AS OF JULY 2009
- TABLE 28 DNA VACCINES CLINICAL TRIALS SUMMARY BY DELIVERY TECHNOLOGY, AS OF JULY 2009
- TABLE 29 DNA VACCINES CLINICAL TRIALS SUMMARY BY VACCINE TYPE, AS OF JULY 2009
- TABLE 30 DNA VACCINES CLINICAL TRIALS SUMMARY BY VACCINE TYPE AND INDICATION, AS OF JULY 2009
- CANCER DNA VACCINE CLINICAL TRIALS
- TABLE 31 CANCER DNA VACCINES CLINICAL TRIALS, AS OF 2009
- TABLE 31 (CONTINUED)
- TABLE 31 (CONTINUED)
- Melanoma
- Melanoma (Continued)
- Prostate Cancer
- Breast Cancer
- Multiple Cancers
- INFECTIOUS DISEASE DNA VACCINES
- TABLE 32 INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
- TABLE 32 (CONTINUED)
- HSV
- HPV
- Influenza
- Influenza (Continued)
- Influenza (Continued)
- SARS
- Dengue
- TABLE 33 DENGUE VACCINE LANDSCAPE, AS OF JULY 2009
- HBV
- TABLE 34 HBV THERAPEUTIC LANDSCAPE, AS OF JULY 2009
- HBV (Continued)
- HCV
- Japanese Encephalitis
- TABLE 35 JAPANESE ENCEPHALITIS VACCINE LANDSCAPE, AS OF JULY 2009
- CMV
- TABLE 36 CMV VACCINE LANDSCAPE, AS OF JULY 2009
- HIV
- TABLE 37 HIV DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
- TABLE 37 (CONTINUED)
- TABLE 37 (CONTINUED)
- TABLE 37 (CONTINUED)
- HIV (Continued)
- BIODEFENSE DNA VACCINES
- TABLE 38 BIODEFENSE DNA VACCINES CLINICAL TRIALS, AS OF JULY 2009
- ANIMAL HEALTH DNA VACCINES
- TABLE 39 ANIMAL HEALTH DNA VACCINES CLINCAL PIPELINE, AS OF JULY 2009
- TABLE 40 WEST NILE VIRUS HUMAN VACCINES LANDSCAPE, AS OF JULY 2009
Chapter-6: DNA VACCINE INDUSTRY
- VACCINE INDUSTRY STRUCTURAL SHIFTS
- TABLE 41 VACCINE INDUSTRY STRUCTURAL SHIFTS
- INDUSTRY STRUCTURE
- TABLE 42 VACCINE INDUSTRY STRUCTURE: TRADITIONAL VERSUS EMERGING
- FIGURE 10 MARKETING OF APPROVED VACCINES IN THE UNITED STATES, 2009 (%)
- TABLE 43 COMPARISON OF VACCINES AND PHARMACEUTICALS BUSINESSES
- INDUSTRY STRUCTURE (CONTINUED)
- DNA VACCINE INDUSTRY COMPETITORS
- TABLE 44 DNA VACCINE INDUSTRY COMPETITOR POSITION
- DNA VACCINE COMMERCIAL VALUE CHAIN
- FIGURE 11 DNA VACCINE COMMERCIAL VALUE CHAIN
- DNA VACCINE COMPETITOR STRATEGIC POSITIONING
- TABLE 45 LARGE PHARMA VACCINE COMPANY STRATEGIC FOCUS
- TABLE 46 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
- TABLE 47 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC MARKET FOCUS
- TABLE 47 (CONTINUED)
- TABLE 48 SPECIALIZED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS
- INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES
- TABLE 49 INDUSTRY ACQUISITIONS AND MERGERS, 2006 - 2009
- INDUSTRY ACQUISITIONS AND ...... (CONTINUED)
- TABLE 50 DNA VACCINE STRATEGIC ALLIANCES
- INDUSTRY ACQUISITIONS AND ...... (CONTINUED)
Chapter-7: DNA VACCINE MARKETS
- GROWTH DRIVING FORCES
- TABLE 51 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES
- MARKET FORECASTS
- OVERVIEW
- TABLE 52 GLOBAL VALUE OF PHARMACEUTICAL MARKET BY TYPE, THROUGH 2014 ($ MILLIONS)
- Overview (Continued)
- DNA VACCINE MARKETS BY END USE
- TABLE 53 GLOBAL VALUE OF DNA VACCINES BY END USE, THROUGH 2014 ($ MILLIONS)
- DNA VACCINE RESEARCH TOOLS MARKETS
- TABLE 54 GLOBAL VALUE OF DNA VACCINES RESEARCH TOOLS MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- DNA VACCINE CLINICAL MARKETS
- TABLE 55 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS)
- Strategic Positioning
- FIGURE 12 DNA VACCINE STRATEGIC MARKET GRID
- Allergies
- TABLE 56 DNA VACCINE ALLERGY MARKET OPPORTUNITIES
- Cancer Therapeutics
- TABLE 57 CAUSE OF DEATH, WORLDWIDE, 2004 AND 2030 (% OF ALL DEATHS)
- Infectious Diseases
- DNA CANCER VACCINES MARKET
- TABLE 58 GLOBAL VALUE OF CANCER CLINICAL DNA VACCINES BY INDICATION, THROUGH 2014 ($ MILLIONS)
- TABLE 59 DNA VACCINE CANCER MARKET OPPORTUNITIES
- DNA Cancer Vaccines Market (Continued)
- Melanoma
- Solid Tumors (Including Ovarian, Breast and Small-Cell Lung Cancer)
- Pancreatic Cancer
- INFECTIOUS DISEASE DNA VACCINE MARKETS
- TABLE 60 GLOBAL VALUE OF INFECTIOUS DISEASE CLINICAL DNA VACCINES MARKET BY INDICATION, THROUGH 2014 ($ MILLIONS)
- CMV
- HBV
- HPV
- HCV
- HIV
- ANIMAL HEALTH DNA VACCINE MARKETS
- TABLE 61 GLOBAL VALUE OF ANIMAL HEALTH CLINICAL DNA VACCINES MARKET, BY INDICATION, THROUGH 2014 ($ MILLIONS)
- Canine Melanoma
- Equine West Nile Virus
- Leishmaniasis
- Feline Leukemia Virus
- Fish Vaccine Adjuvants
- BIODEFENSE DNA VACCINE MARKETS
- TABLE 62 GLOBAL VALUE OF BIODEFENSE CLINICAL DNA VACCINES MARKET, BY END USE, THROUGH 2014 ($ MILLIONS)
- Biodefense DNA Vaccine Markets (Continued)
- Biodefense DNA Vaccine Markets (Continued)
- DNA VACCINE MARKETS BY DELIVERY TECHNOLOGY
- TABLE 63 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY DELIVERY TECHNOLOGY, THROUGH 2014 ($ MILLIONS)
- DNA VACCINE MARKET BY FORMAT AND FUNCTION
- TABLE 64 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY VACCINE FORMAT, THROUGH 2014 ($ MILLIONS)
- TABLE 65 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY FUNCTION, THROUGH 2014 ($ MILLIONS)
- DNA VACCINES MARKET BY GEOGRAPHY
- TABLE 66 GLOBAL VALUE OF DNA VACCINES MARKET, BY GEOGRAPHICAL REGION, THROUGH 2014 ($ MILLIONS)
Chapter-8: PATENT STATUS
- INTRODUCTION
- FIGURE 13 PATENT SCOPE FOR DNA VACCINES
- DNA VACCINE PATENTS BY COMPANY AND TECHNOLOGY SUBCLASS
- FIGURE 14 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS AND PATENT APPLICATIONS, AS OF JULY 2009
- FIGURE 15 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS BY TECHNOLOGY SUBCLASS AND PATENT APPLICATIONS, AS OF JULY 2009
- DNA VACCINE PATENTS BY COMPANY ...... (CONTINUED)
- FIGURE 16 U.S., EP, AND WO INTEGRATED BIOTECHNOLOGY COMPANY DNA VACCINE-RELATED PATENTS BY TECHNOLOGY SUBCLASS, AS OF JULY 2009
- ANTIGENS AND ASSOCIATED PDNA
- ANTIGENS AND ASSOCIATED PDNA (CONTINUED)
- TABLE 67 FUNDAMENTAL DNA INFLUENZA VACCINE PATENTS
- DNA VACCINE PATENTS BY GEOGRAPHY
- FIGURE 17 GEOGRAPHICAL REGIONS IN WHICH PATENTS HAVE BEEN GRANTED AND PATENT APPLICATIONS FILEDFOR INTEGRATED BIOTECHNOLOGY COMPANIES, AS OF JULY 2009 (%)
- KEY INDUSTRY PATENTS ON OTHER PARTS OF THE VALUE CHAIN
- TABLE 68 FUNDAMENTAL PATENTS ON DNA VACCINE DELIVERY, TARGETING, AND ADJUVANTS
- LITIGATION STATUS
- TABLE 69 IP LITIGATION STATUS
- IP POSITION OF SELECTED DNA VACCINE COMPANIES
- GENEART
- GENEXINE
- TABLE 70 GENEXINE PATENT FAMILIES
- IMMUNOMIC THERAPEUTICS, INC. (ITI)
- VICAL
Chapter-9: COMPANY PROFILES
- ADIMMUNE
- ALDEVRON, LLC
- ALTEA THERAPEUTICS
- ALTHEA TECHNOLOGIES, INC.
- ANGES MG, INC.
- AVAX TECHNOLOGIES
- BACILLIGEN, INC.
- BAVARIAN NORDIC A/S
- BAYHILL THERAPEUTICS
- TABLE 71 BAYHILL DNA VACCINE PIPELINE
- BIGDNA, LTD.
- BIOJECT MEDICAL TECHNOLOGIES, INC.
- CHANGCHUN BAIKE PHARMACEUTICAL CO., LTD.
- COBRA BIOMANUFACTURING, PLC
- CRUCELL
- CYTOGENIX, INC.
- TABLE 72 CYTOGENIX DNA VACCINE PRECLINICAL PIPELINE
- CYTO PULSE SCIENCES, INC.
- TABLE 73 CYTO PULSE PIPELINE
- PROSTATE CANCER STUDY
- COLORECTAL CANCER STUDY
- TOLERANCE STUDIES
- HIV STUDY
- CYTRX CORP.
- DENDREON CORP.
- DYNAVAX TECHNOLOGIES
- THE EUROVACC FOUNDATION
- FIT BIOTECH OYJ, PLC
- GENEART AG
- TABLE 74 GENEART STRATEGIC ALLIANCES
- GENEART AG (CONTINUED)
- GENETIC IMMUNITY
- TABLE 75 GENETIC IMMUNITY DNA VACCINE PIPELINE
- GENEXINE
- TABLE 76 GENEXINE DNA VACCINE PIPELINE
- TABLE 77 GENEXINE PATENT FAMILIES
- TABLE 77 (CONTINUED)
- IL-12 MUTANT
- EFFICIENT DNA AND RAD VECTORS
- SAFE ADENOVIRAL VECTOR
- GENOMIDEA, INC.
- GENOVAC GMBH
- GENOVAC GMBH (CONTINUED)
- GENVEC, INC.
- GEOVAX LABS
- GLAXOSMITHKLINE
- GLAXOSMITHKLINE (CONTINUED)
- GREENPAK BIOTECH, LTD.
- HENDERSON MORLEY, PLC
- ICHOR MEDICAL SYSTEMS, INC.
- TABLE 78 ICHOR DNA VACCINE PIPELINE
- IMMUNOGENETIX THERAPEUTICS, INC.
- IMMUNOMIC THERAPEUTICS, INC.
- TABLE 79 IMMUNOMIC DNA VACCINE PIPELINE
- JRC-LAMP-VAX
- SRW-LAMP-VAX
- TABLE 80 ITI STRATEGIC ALLIANCES
- IMMUNOVACCINE TECHNOLOGIES, INC.
- IN CELL ART
- INDIAN IMMUNOLOGICALS
- INTERCELL AG
- INVIVOGEN
- JUVARIS BIOTHERAPEUTICS, INC.
- TABLE 81 JUVARIS DNA VACCINE PIPELINE
- LENTIGEN CORP.
- LIPOXEN, PLC
- MANNKIND CORP.
- MANNKIND CORP. (CONTINUED)
- MEDICAL MARKETING INTERNATIONAL GROUP, PLC
- MERCK
- TABLE 83 MERCK DNA VACCINE PIPELINE
- MERIAL
- MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
- MOLOGEN AG
- MULTIMERIC BIOTHERAPEUTICS, INC.
- NATURE TECHNOLOGY CORP.
- NIH VACCINE RESEARCH CENTER
- NOVARTIS
- OXFORD BIOMEDICA, PLC
- PFIZER
- PHYTOVATION BV
- PLASMIDFACTORY GMBH & CO.
- PROFECTUS BIOSCIENCES, INC.
- QED BIOSCIENCE, INC.
- SANOFI-AVENTIS
- STATENS SERUM INSTITUT
- SUPRATEK PHARMA
- TRIPEP
- TABLE 84 TRIPEP THERAPEUTIC DNA VACCINE PIPELINE
- VAXGEN, INC.
- VAXXION THERAPEUTICS, INC.
- VAXONCO, INC.
- VECTURA GROUP, PLC
- VGX PHARMACEUTICALS, INC.
- VGX PHARMACEUTICALS, INC. (CONTINUED)
- TABLE 85 INOVIO AND VGX DNA VACCINE CLINICAL TRIALS, AS OF JULY 2009
- VGX PHARMACEUTICALS, INC. (CONTINUED)
- VGXI, INC.
- VICAL, INC.
- TABLE 86 VICAL STRATEGIC ALLIANCES
- TABLE 87 VICAL DNA VACCINE PIPELINE
- TABLE 87 (CONTINUED)
- FIGURE 18 VICAL LINEAR DNA VACCINE STRATEGIC POSITIONING
- VIROMED CO., LTD.
- VIROMED CO., LTD. (CONTINUED)
|
Related Report
|
View Cart
